Synthetic gonadotropin-releasing hormone (GnRH) agonist that stimulates secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Repeated administration causes desensitization of pituitary GnRH receptors resulting in inhibition of gonadotropin release and decreased steroid hormone synthesis. Induces atrophy and regression of experimentally induced endometriosis in rat and shrinks hypertrophic tissue in benign prostatic hyperplasia.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Nafarelin acetate: a gonadotrophin-releasing hormone agonist for the treatment of endometriosis.
Letassy et al.
Effect of gonadotrophin-releasing hormone agonists, nafarelin, buserelin, and leuprolide, on experimentally induced endometriosis in the rat.
Mizutani et al.
Int.J.Fertil.Menopausal Stud., 1995;40:106
Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.
Chrisp and Goa